CRYO-CELL Signs Exclusive License to Market New Stem Cell Service

17 October 2005

CRYO-CELL International,
Inc. (OTC Bulletin Board: CCEL) (the "Company") announced today that it has
signed an exclusive Strategic Relationship Agreement with Plureon Corporation,
a private biotechnology company, to provide collection and preservation of
Plureon's proprietary stem cells. Under the terms of the agreement, CRYO-CELL
will develop the proprietary methodology to collect, process and cryogenically
preserve Plureon Stem Cells (PSCs) collected from placental tissue at the time
of birth. The agreement establishes exclusive license rights for CRYO-CELL to
market the Plureon service in the United States, and first-rights-of-refusal
for other global markets.
PSCs are a promising and novel type of stem cell discovered by researchers
working in the Laboratory for Cell Therapy and Tissue Engineering at
Children's Hospital Boston (a Harvard Medical School teaching affiliate in
Boston, MA). Plureon Corporation acquired the exclusive worldwide rights to
the Children's Hospital patent applications pertaining to this novel stem cell
for both collection/banking as well as therapeutic development.
Researchers believe that Plureon cells represent great promise as an
alternative to embryonic stem cells in the development of human cellular
therapies. PSCs are not sourced from human embryonic tissues, but like
embryonic stem cells, are lineage negative and reproduce rapidly. In the
laboratory, PSCs have been differentiated into many other cell types,
including bone, cardiac muscle, skeletal muscle, nerves, liver, and pancreatic
cells. Even after hundreds of population doublings, PSCs appear to remain
stable and retain their key characteristics.
PSCs differ from embryonic stem cells in other aspects, as well. Whereas
embryonic cells have been shown to form teratomas when implanted into animals,
Plureon cells are non-cancer forming. And, because PSCs are collected without
harm to an embryo or fetus, they do not give rise to the ethical controversy
surrounding embryonic stem cells.
PSCs have demonstrated strong potential in developing next-generation
medical treatments for presently incurable diseases. Researchers have already
demonstrated that PSCs have the ability to cure diabetes in small animals.
This finding attracted the interest of several large pharmaceutical and life
sciences companies, leading to Plureon's October 14, 2005 announcement of a
research and development agreement in the field of diabetes with BD (Becton
Dickinson and Company). Plureon is also researching the use of PSCs in
treating a host of other diseases, disabilities, and injuries.
CRYO-CELL intends to launch the Plureon service in early 2006, in
combination with its industry-leading U-Cord(R) service. CRYO-CELL expects to
charge a fee for cell collection, processing and storage, and pay royalties to
Plureon for sub-licensing the underlying technology. Soon parents will have
the unique opportunity to collect both cord blood and PSCs from placental
tissue for their future therapeutic potential. As with the Company's
industry-leading cord blood stem cell preservation service, placental tissue

would otherwise be discarded as medical waste, and its collection causes no
harm to either mother or baby.
Over the past fifteen years, cord blood stem cells have increasingly been
used to successfully treat over 70 diseases. The majority of these diseases
have been related to blood and immune system disorders, and researchers have
been recently encouraged by cord blood's potential in other diseases,
including neurological disorders and cardiac conditions. PSCs offer distinct
advantages over cord blood stem cells: they have more plasticity (the ability
to become multi-lineage) and can be easily cultured to multiply. Because of
this, Plureon Stem Cells collected at birth may be later removed from
cryogenic storage and serve as a source of stem cells for multiple future
therapeutic applications. Although, to date, PSCs have not been used in human
therapies, laboratory animal studies are encouraging.
"We believe the strategic alliance between CRYO-CELL and Plureon
represents a pivotal development in CRYO-CELL's history, as well as the newly
emerging frontier of regenerative science. Plureon's world-renowned research
affiliates have discovered a cell that has the potential to transform cellular
medicine," stated Mercedes Walton, Chairman and CEO of CRYO-CELL.
"The expected early 2006 launch of CRYO-CELL's enhanced service will
combine our industry-leading U-Cord(R) service with the Plureon Stem Cell
service," Ms. Walton continued, "We believe this innovative new service will
uniquely position CRYO-CELL in an industry-of-one as 'THE Stem Cell Solution
Source'. In addition to providing sourcing options for potential stem cell
solutions, CRYO-CELL intends to offer families a prospective healthcare
management asset that may possibly increase in value as future therapeutic
applications emerge. We are very excited to be at the forefront of this
exciting new technology that we believe will serve to accelerate the Company's
growth while potentially providing an extended and improved quality of life
for CRYO-CELL clients."
Hal Eason, Chairman, President and CEO of Plureon, commented, "We are
extremely pleased to collaborate with CRYO-CELL in introducing the Plureon
Stem Cell service to the marketplace. This relationship will provide parents
with the opportunity to preserve at birth not just cord blood, but also unique
placental cells that could dramatically impact the future health of their
family. Also, CRYO-CELL's capable management team, proven track record, and
market leadership give us the assurance that this service will be made
available to the widest possible audience. While CRYO-CELL focuses on
providing the collection and preservation service, Plureon will focus on
extending the research and enhancing the therapeutic potential of the banked
cells."

About CRYO-CELL International, Inc.
Based in Oldsmar, Florida, CRYO-CELL is the world's largest U-Cord(R) stem
cell banking firm, offering premium-quality, superior value cord blood
preservation exclusively for the benefit of newborn babies and possibly other
members of their family. With over 100,000 clients worldwide, CRYO-CELL is
accredited by the AABB and believes the Company is the first private cord
blood bank to operate in a newly constructed state-of-the-art current Good
Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant
facility, well in advance of newly established Food and Drug Administration
(FDA) regulation.
CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol: CCEL.
Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit http://www.CRYO-CELL.com .

About Plureon
Plureon is a privately held biotechnology company based in Winston-Salem,
North Carolina. Plureon has licensed from Children's Hospital Boston (a
Harvard Medical School teaching affiliate) the exclusive worldwide rights to
its patents pertaining to a novel type of stem cell discovered at the
hospital's Laboratory for Cell Therapy and Tissue Engineering. Plureon's stem
cells are not sourced from human embryonic tissues, yet may be differentiated
into many other cell types, including bone, cardiac muscle, nerves, liver, and
pancreatic cells.

Forward-Looking Statement
Statements wherein the terms "believes," "intends," "projects" or
"expects" as used are intended to reflect "forward-looking statements" of the
Company. The information contained herein is subject to various risks,
uncertainties and other factors that could cause actual results to differ
materially from the results anticipated in such forward-looking statements or
paragraphs, many of which are outside the control of the Company. These
uncertainties and other factors include any adverse effect or limitations
caused by any governmental regulations, proceedings or actions, foreign and
domestic; any continued or increased losses, or any inability to obtain
acceptable financing, where desirable in the future, in connection with our
operating or growth plans; any increased competition in our business; any
decrease or slowdown in the number of people seeking to store umbilical cord
blood stem cells or decrease in the number of people paying annual storage
fees; the effect of any future reduced cash position and future inability to
access borrowings; any adverse impacts on our revenue or operating margins due
to the costs associated with increased growth in our business, including the
possibility of unanticipated costs relating to the move into our new facility
or the operation of the facility; any adverse developments impacting our
continued relationship with and success of our licensees, foreign affiliates
or investments in, or relationships with, foreign companies; any inability to
achieve increases in revenue or earnings from umbilical cord blood stem cell
storage; any future inability to substantially achieve the objectives expected
from the successful implementation of our strategy; any decline in public
market interest in the Company's business sector; any added requirements
imposed on us by new laws or SEC regulations and costs thereof; any
technological breakthrough or medical breakthrough that would render the
Company's business of stem cell preservation obsolete; any material failure or
malfunction in our storage facilities; any natural disaster such as a tornado,
other disaster (fire) or act of terrorism that adversely affects stored
specimens; the potential impact of negative market influences on the Company's
portfolio of cash, cash equivalents and marketable securities; the costs
associated with defending or prosecuting litigation matters and any material
adverse result from such matters; decreases in asset valuations; any continued
negative effect from adverse publicity in the past year regarding the
Company's business operations; any new technology rendering the Company's
patented equipment or business obsolete; any performance failures related to
the Company's equipment or operations; any negative consequences resulting
from deriving, shipping and storing specimens at a second location; any
negative effect from the filed class action shareholder lawsuits; and other
risks and uncertainties. The foregoing list is not exhaustive, and the Company
disclaims any obligations to subsequently revise any forward-looking
statements to reflect events or circumstances after the date of such
statements. Readers should carefully review the risk factors described in
other documents the Company files from time to time with the Securities and
Exchange Commission, including the most recent Annual Report on Form 10-KSB,
Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by
the Company.